Janna Sand-Dejmek, member
Board member since 2020. Janna Sand-Dejmek is head of Novarti’s early clinical oncology development department in Shanghai, has a medical degree and specialist medical training from Lund University and Skåne University Hospital. She has a PhD in experimental pathology and did her post-doc at the Dana-Farber Cancer Institute in Boston. Her research focuses on intracellular signaling pathways of importance for oncogenesis and metastasis. Since 2012, she has been active in the pharmaceutical industry, where she has held oncology roles in both preclinical research, early and late clinical development as well as medical affairs.
Other assignments: Chair Sand Medical AB.
Shareholdings: 3 963 shares.